Induction of hepatitis B virus surface antigen‐specific cytotoxic T lymphocytes can be up‐regulated by the inhibition of indoleamine 2, 3‐dioxygenase activity |
| |
Authors: | Hiroyasu Ito Tatsuya Ando Kazuki Ando Tetsuya Ishikawa Kuniaki Saito Hisataka Moriwaki Mitsuru Seishima |
| |
Affiliation: | 1. Department of Informative Clinical Medicine, Gifu University Graduate School of Medicine, , Gifu, Japan;2. Department of Medical Technology, Nagoya University School of Health Sciences, , Nagoya, Aichi, Japan;3. Human Health Sciences, Graduate School of Medicine and Faculty of Medicine, Kyoto University, , Kyoto, Japan;4. First Department of Internal Medicine, Gifu University Graduate School of Medicine, , Gifu, Japan |
| |
Abstract: | Cytotoxic T lymphocytes (CTLs) are thought to be major effectors involved in viral clearance during acute infections, including hepatitis B virus (HBV) infection. A persistent HBV infection is characterized by a lack of or a weak CTL response to HBV, which may be reflective of tolerance to HBV. Efficient induction of HBV‐specific CTLs leads to the clearance of HBV in patients with a chronic HBV infection. Previously, we reported that α‐galactosylceramide (α‐GalCer), a specific natural killer T (NKT) cell agonist, enhanced the induction of HBV surface antigen (HBsAg)‐specific CTLs. In the present study, we found that inhibition of indoleamine 2,3‐dioxygenase (IDO) activity enhanced the induction of HBsAg‐specific CTLs after immunization with HBsAg and α‐GalCer. The administration of HBsAg and α‐GalCer increased the production of interleukin‐2 and interleukin‐12b, which are crucial for the induction of HBsAg‐specific CTLs. The production of these cytokines was more strongly enhanced in IDO knockout mice compared with wild‐type mice. In addition, α‐GalCer induced the production of IDO in CD11b+ cells, and these cells inhibited proliferation of HBsAg‐specific CTLs. Our results lead to strategies for improving the induction of HBsAg‐specific CTLs. |
| |
Keywords: | 3‐dioxygenase cytotoxic T lymphocyte hepatitis B virus indoleamine 2 vaccination |
|
|